MedaSystems is a developer of a cloud-based platform that facilitates the management of requests for experimental therapies. The platform is designed to streamline various processes through configurable workflows and a form builder that captures complex, structured, therapy-specific data. It incorporates task management and tracking features, and integrates with machine learning libraries, enabling collaboration between manufacturers and physicians. MedaSystems supports a range of initiatives, including expanded access programs, named patient programs, investigator-sponsored trial requests, and post-trial access, thereby enhancing global access to investigational medicines.
Building the next generation of biomarkers for precision oncology
Risklick is develops a first-of-the-kind data-driven tool to allow end-users to identify similar Clinical trials(CTs) and assess risks in early steps of the protocol design. CTs are used to determine the efficacy and safety of an experimental treatment; however, up to 90% of them fail in the early stage of protocol design and the nature and complexity of CTs make risk assessment difficult and time-consuming.
MedaSystems is a developer of a cloud-based platform that facilitates the management of requests for experimental therapies. The platform is designed to streamline various processes through configurable workflows and a form builder that captures complex, structured, therapy-specific data. It incorporates task management and tracking features, and integrates with machine learning libraries, enabling collaboration between manufacturers and physicians. MedaSystems supports a range of initiatives, including expanded access programs, named patient programs, investigator-sponsored trial requests, and post-trial access, thereby enhancing global access to investigational medicines.
Patient-centric cancer data and analytics platform for translational cancer biologists
Altis Labs is a computational imaging company that leverages artificial intelligence to enhance clinical trials. By developing an advanced software platform, Altis enables biopharmaceutical companies to process their clinical trial data in real-time, predicting drug efficacy with improved accuracy. The company's unique approach is underpinned by the creation of a comprehensive multimodal training database that integrates longitudinal imaging with demographic, clinical, and molecular data, as well as extensive outcomes data. This innovative use of AI allows biopharma firms to measure treatment effects more effectively from existing data, thereby increasing the speed and success rate of late-stage trials and reducing the overall time and cost associated with bringing new drugs to market.
Concr is a techbio company focused on enhancing cancer treatment by predicting patient responses to various therapies. Utilizing methods from astrophysics, Concr's innovative approach allows for iterative learning from diverse data sources throughout a drug's clinical journey, resulting in accurate multi-modal tumor models without relying on extensive data sets. Its cloud-native platform, FarrSight®, enables researchers to simulate clinical trials, predict therapeutic responses and biomarkers, and conduct standard bioinformatics analyses. This technology aims to identify optimal treatments for individual patients, reduce treatment resistance, and facilitate personalized cancer management. Headquartered in London with a subsidiary in Brisbane, Australia, Concr is backed by several investors, including the University of Cambridge Enterprise and Oncology Ventures.
Genialis, Inc. is a computational precision medicine company that specializes in developing a web-based software platform for biological data management and analysis. Founded in 2015 and based in Houston, Texas, the platform provides a suite of visual analytics and bioinformatics tools, facilitating the storage, analysis, and sharing of biological data while ensuring transparency and security. The system automates primary analyses to enhance reproducibility and allows non-computational experts to access advanced downstream analyses. Genialis focuses on unraveling complex biology to identify actionable biomarkers, which aids pharmaceutical companies in developing effective drugs and diagnostics that improve treatment decisions. The company's efforts aim to enhance translational research and clinical development, ultimately benefiting patients and their families.
Iktos is a French company focused on artificial intelligence and robotic solutions for medicinal chemistry and drug design. It offers a proprietary generative AI technology that optimizes molecule design for small molecule discovery projects, significantly enhancing productivity in pharmaceutical research and development. Iktos provides its innovative solutions through its SaaS platforms, Makya™ for generative drug design and Spaya™ for retrosynthesis, while also engaging in strategic partnerships with pharmaceutical companies to accelerate drug discovery. Additionally, Iktos has developed an AI-driven synthesis automation platform, Iktos Robotics, which expedites the Design-Make-Test-Analyze cycle in drug development. The company is also advancing its own pipeline of drug candidates aimed at oncology and autoimmune diseases. In March 2023, Iktos secured a significant financing round, and in July 2024, it enhanced its capabilities by acquiring Synsight, which adds a biology platform for discovering drugs targeting Protein-Protein and RNA-Protein interactions.
YonaLink operates a global network of over 30,000 medical centers, focusing on the collection and management of clinical trial data. The company offers a platform that streamlines the migration of clinical research data from electronic health records to electronic data capture systems, ensuring a secure and automated process. By enhancing trial efficiency and data quality, YonaLink alleviates the burden on medical center staff and broadens access to innovative patient care opportunities. Its solutions also aim to accelerate drug and medical device development while promoting patient diversity and enrollment in clinical trials, ultimately enabling healthcare providers and researchers to achieve faster and more accurate data capture.
Mika is a digital platform that empowers cancer patients. It aims to help improve cancer patients' mental health and well-being. Mika was created in collaboration with leading research institutions. The company was established in 2017 and is headquartered in Berlin, Germany.
VivoSense, also known as Vivonoetics, is a data analysis and software company focused on providing wearable sensor physiological monitoring solutions for research and clinical trials. The company develops digital clinical measures designed to enhance patient research and care by delivering digital biomarkers derived from wearable sensor data. This platform allows researchers to collect and analyze real-world data accurately, facilitating informed decision-making and risk evaluation associated with various medical treatments in regulated clinical environments. Through its innovative approach, VivoSense aims to improve the efficiency and effectiveness of clinical research.
Nucleai Ltd. is a spatial biology company that has developed an AI-powered pathology platform focused on enhancing drug development and improving patient outcomes. Founded in 2017 and headquartered in Tel Aviv-Yafo, Israel, Nucleai's technology utilizes unique tissue datasets and machine learning algorithms to analyze biopsy samples and detect various cancers, including prostate, breast, and gastrointestinal diseases. The platform aims to improve the interpretation of pathology results, thereby increasing the efficacy of clinical trials and fostering better patient care. Nucleai collaborates with leading pharmaceutical companies, licensing its platform for internal use and participating in biomarker discovery projects. By transforming healthcare through artificial intelligence, Nucleai strives to enable researchers to identify novel biomarkers that predict therapeutic responses and enhance understanding of complex biological phenomena.
VeriSIM Life, Inc. is a biotechnology company based in San Francisco, California, that specializes in developing disease-specific biosimulation models to enhance drug development processes. Founded in 2017, the company utilizes its proprietary BIOiSIM platform to predict the clinical outcomes of new drugs prior to clinical trials, thereby replacing traditional animal testing methods. By employing artificial intelligence, VeriSIM Life aims to improve the accuracy and efficiency of drug development, ultimately contributing to personalized healthcare solutions. Their offerings are tailored to meet the needs of both pre-clinical and clinical programs, focusing on small molecules, large molecules, and viruses to facilitate better treatment options and increase human life expectancy.
Mekonos Inc. specializes in the design, development, and production of gene and cell therapies, focusing on a proprietary cell-engineering platform that utilizes advanced silicon technology. Founded in 2017 and based in San Francisco, the company has created an integrated system-on-a-chip, which incorporates micro-electromechanical systems (MEMS) to enable the precise injection of single cells using nanoneedles in a parallel architecture. This innovative approach aims to industrialize genome editing and enhance drug discovery and development processes. Mekonos' technology allows for scalable and reliable manufacturing of engineered therapies aimed at addressing genetic diseases, including various forms of cancer, and supports healthcare providers in delivering diverse therapeutic molecules across multiple cell types.
Carevive Systems, Inc. is a company that develops a platform designed to enhance cancer care delivery and patient engagement. The platform includes Carevive PROmpt, which serves as a cancer clinical practice and patient engagement software for treatment planning, symptom management, and survivorship care, as well as offering analytics and evidence-based care plans. It also features a Treatment Care Plans engine, which utilizes rules technology for personalized treatment strategies, and a Navigation/Care Coordination module that facilitates patient eligibility tracking and care plan adherence. Additionally, Carevive Systems provides tools for risk stratification, symptom triage, and patient symptom trending, allowing clinicians to monitor patient progress effectively. The company, based in North Miami, Florida, was incorporated in 2013 and rebranded from On Q Health, Inc. in 2015. Through its solutions, Carevive Systems aims to improve clinical outcomes and support oncology practices in adapting to value-based care models.
Voluntis, Inc. is a healthcare software company headquartered in Cambridge, Massachusetts, that specializes in developing digital therapeutic solutions for various medical conditions, including diabetes and oncology. Founded in 2001, Voluntis provides innovative tools such as Insulia, which offers personalized insulin dose recommendations for type 2 diabetes patients, and Diabeo, designed for type 1 and type 2 patients on basal-bolus insulin regimens. These solutions utilize algorithmic calculations tailored to individual patient needs, incorporating real-time data like blood glucose levels. The company aims to enhance patient monitoring and support by leveraging advanced information and communication technologies. With over 600,000 patients managed and more than 50 programs deployed, Voluntis emphasizes a patient-centric approach to healthcare, striving to improve medical outcomes and healthcare system efficiency through its digital health solutions.
Oncomfort’s solution for digital sedation is a completely new method for relieving patients’ pain and anxiety before, during and after medical procedures. This revolutionising digital therapy combines clinical hypnotherapy and integrative therapeutic techniques through Virtual Reality.
Nucleai Ltd. is a spatial biology company that has developed an AI-powered pathology platform focused on enhancing drug development and improving patient outcomes. Founded in 2017 and headquartered in Tel Aviv-Yafo, Israel, Nucleai's technology utilizes unique tissue datasets and machine learning algorithms to analyze biopsy samples and detect various cancers, including prostate, breast, and gastrointestinal diseases. The platform aims to improve the interpretation of pathology results, thereby increasing the efficacy of clinical trials and fostering better patient care. Nucleai collaborates with leading pharmaceutical companies, licensing its platform for internal use and participating in biomarker discovery projects. By transforming healthcare through artificial intelligence, Nucleai strives to enable researchers to identify novel biomarkers that predict therapeutic responses and enhance understanding of complex biological phenomena.
Carevive Systems, Inc. is a company that develops a platform designed to enhance cancer care delivery and patient engagement. The platform includes Carevive PROmpt, which serves as a cancer clinical practice and patient engagement software for treatment planning, symptom management, and survivorship care, as well as offering analytics and evidence-based care plans. It also features a Treatment Care Plans engine, which utilizes rules technology for personalized treatment strategies, and a Navigation/Care Coordination module that facilitates patient eligibility tracking and care plan adherence. Additionally, Carevive Systems provides tools for risk stratification, symptom triage, and patient symptom trending, allowing clinicians to monitor patient progress effectively. The company, based in North Miami, Florida, was incorporated in 2013 and rebranded from On Q Health, Inc. in 2015. Through its solutions, Carevive Systems aims to improve clinical outcomes and support oncology practices in adapting to value-based care models.
BC Platforms provides a data and technology platform designed for life sciences and healthcare companies to access, manage, and analyze clinical and omics data. Its Data Access Platform offers valuable resources, including real-world data, clinical data, and genomic information, through a data-as-a-service model. The company's Data Partner Network encompasses over 22 million life-years of meticulously curated patient data from various global sources. This extensive data access allows pharmaceutical companies to enhance research and development processes, accelerating the transition from early discovery to clinical and post-market evaluations. BC Platforms also offers technology solutions that enable healthcare providers and life science organizations to manage and analyze complex genomic data, ensuring compliance with local privacy regulations and compatibility with relevant technical standards. Through its innovative platform, BC Platforms aims to improve decision-making in drug development and delivery, helping to address significant health challenges effectively.
Kaiku Health Oy is a digital health company based in Helsinki, Finland, focused on enhancing the quality of life for patients, particularly those undergoing cancer treatment. Founded in 2012, the company offers a user-centered platform that facilitates communication between patients and medical staff in multiple languages, including Swedish, English, German, and Finnish. Its software is designed to monitor patient-reported outcomes and track symptoms intelligently, allowing clinics to optimize care through timely interventions and improved efficiency. Kaiku Health serves over 30 hospitals and clinics across Finland, Sweden, and Switzerland, helping to streamline workflows and prioritize clinical actions. The company evolved from its original name, Netmedi Oy, in 2017 and operates as a subsidiary of Elekta AB. A dedicated team of over 20 employees drives its mission, supported by various venture capital funds and the Finnish Funding Agency for Innovation.
ABAC Therapeutics S.A., based in Barcelona, Spain, specializes in the development of precision antimicrobial agents aimed at treating multidrug-resistant (MDR) Gram-negative infections. Established in 2014, the company utilizes its innovative PasNas drug discovery platform to identify pathogen-specific antibacterial properties of various molecules. This platform not only focuses on potent antibacterial activity but also emphasizes the importance of favorable pharmacokinetics and toxicological profiles to enhance the likelihood of success in clinical development. ABAC Therapeutics seeks to provide first-in-class therapeutic alternatives for patients suffering from infections caused by antibiotic-resistant bacterial pathogens, particularly targeting the significant challenge posed by the major MDR Gram-negative bacteria. As of November 2019, the company operates as a subsidiary of Tibidabo Ventures.
BC Platforms provides a data and technology platform designed for life sciences and healthcare companies to access, manage, and analyze clinical and omics data. Its Data Access Platform offers valuable resources, including real-world data, clinical data, and genomic information, through a data-as-a-service model. The company's Data Partner Network encompasses over 22 million life-years of meticulously curated patient data from various global sources. This extensive data access allows pharmaceutical companies to enhance research and development processes, accelerating the transition from early discovery to clinical and post-market evaluations. BC Platforms also offers technology solutions that enable healthcare providers and life science organizations to manage and analyze complex genomic data, ensuring compliance with local privacy regulations and compatibility with relevant technical standards. Through its innovative platform, BC Platforms aims to improve decision-making in drug development and delivery, helping to address significant health challenges effectively.
Coorpacademy S.A. is a Swiss company based in Lausanne, established in 2013. It specializes in developing online training courses and innovative learning solutions, including MOOCs. The company offers a learning experience platform that features a diverse catalog of training courses, which are designed to provide short, accessible sessions that users can engage with at any time and on various devices. This platform aims to revolutionize digital learning for employees by delivering customized content tailored to individual needs. Coorpacademy was founded by Frederick Benichou, Jean-Marc Tassetto, and Arnauld Mitre.
Biocartis SA is a molecular diagnostics company based in Lausanne, Switzerland, focused on developing a technology platform for the multiplexed detection of bio-analytes. Established in 2007, Biocartis integrates molecular and immunodiagnostics through its proprietary micro-technology platform. The company offers a range of diagnostic solutions, including the Idylla molecular diagnostic system, which serves oncology and infectious disease applications. Its product portfolio features assays for various mutations, such as EGFR, BRAF, and NRAS, as well as a respiratory panel. These products are designed to enhance clinical practice by facilitating the detection, quantification, and monitoring of bio-molecules associated with disease risk factors and treatment decisions. Biocartis primarily generates revenue through the sale of its diagnostic products.
Gilles Florey and Yann Rodriguez founded KeyLemon in 2008 in Martigny (Switzerland), a region as renowned for its Alpine skiing and scenic beauty as for its entrepreneurial dynamism. They founded KeyLemon on the simple idea that your device should be able to recognize you in a natural and passive way as a human does. rather than you having to constantly re-enter (and remember) a device password. Pioneering biometric authentication solutions via 2D and 3D face recognition for nearly ten years, KeyLemon has continuously pursued its vision for convenient security through effortless user recognition. Over the past decade, the technology company has remained true to this focus. KeyLemon offers biometric authentication solutions that are cutting edge, convenient, secure and continuous. The company’s flagship mobile product, Oasis, makes mobile authentication through face recognition as simple as taking a selfie. The unique client-server and client-only mobile solution has gained traction with developers and manufacturers across industries. In all its solutions, the company strives to improve secure access to high-value transaction services like banking or payment, regardless of device, system or application. KeyLemon remains headquartered in Switzerland, and the company has grown to serve clients across the globe.
Diagnoplex has been founded in 2005 supported by seed financing fron the Novartis Forschungsstiftung, Swiss Confederation CTI project, Canton de Vaud FIT and the Gebert Rüf Stiftung. The company has performed a 140 patient prospective pilot study demonstrating technical and clinical feasibility of its colorectal cancer screening test COLOX as well as its high sensitivity and specificity.
Searchbox is a software company specializing in search technologies, with strong areas of expertise in cognitive sciences, data mining and computer sciences. Through its innovative technologies, Searchbox fundamentally changes the way people interact and consume information. Through highly customizable cloud based search solutions and plugins for Solr, these technologies are readily available for usage with a minimal amount of tinkering.
Neovacs is a biotechnology company established in 1993 as a spin-off from Pierre & Marie Curie University in Paris, founded by Professor Daniel Zagury, a prominent immunologist. The company specializes in developing therapeutic vaccines, known as "Kinoids," aimed at treating various conditions, including autoimmune diseases, allergies, and cancer. Neovacs is recognized for its innovative approach to vaccine development, focusing on creating therapeutic vaccines that stimulate a robust natural polyclonal antibody response, in contrast to conventional treatments that utilize monoclonal antibodies. With a comprehensive patent portfolio, Neovacs is at the forefront of advancing novel therapeutic solutions to combat diseases related to cytokines and immunosuppressive viral proteins.